Sun Pharmaceutical Industries Limited (SUNPHARMA) fair value: what the stock is really worth
We calculate from audited financials what Sun Pharmaceutical Industries Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Sun Pharmaceutical Industries Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 17, 2026.
How to read this chart
60‑month range ₹631.11 – ₹2,001 · fair‑value band ₹1,212 – ₹2,701 · the ₹1,837 price screens below the ₹1,979 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 17, 2026.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally.
Show more
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Stock analysis
Sun Pharmaceutical Industries Limited (SUNPHARMA) currently trades at ₹1,837, while our model-based Fair Value estimate is ₹1,979, implying the stock looks roughly 7.2% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹1,210 per share, and 0 of the 26 models we run sit above the ₹1,837 price.
Bear case: the Asset-Based group reads lowest at ₹233.36, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹1,212 (bear) to ₹2,701 (bull), the price of ₹1,837 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Sun Pharmaceutical Industries Limited reported revenue of ₹585B in FY2026 versus ₹387B in FY2022, a compound +10.9%/yr. Reported net income was ₹115B in FY2026, compounding +36.9%/yr from FY2022.
Key figures
Market cap ₹4.4T (≈ $45.9B) · P/E ratio 38.5 · P/S ratio 7.56 · EPS (TTM) ₹47.74 · Dividend yield 0.9% · Net margin 19.6% · Return on equity 14.7% · Return on assets (EBIT) 24.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 8%, SUNPHARMA screens cheaper than that median.
Fair Value models
Bear ₹1,212Fair Value ₹1,979Bull ₹2,701
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹14.90 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+28.5%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.29% vs 9%, picking up
Profit margin 2004 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.39% → 23%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.2%
Yearly sales growth analysts expect, extended to five years.
News mood ⓘNews mood, the average tone of recent news (55 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Sun Pharmaceutical Industries Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−6% · Above median
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)20% · Top 25%
Operating margin (TTM)19% · Top 25%
Growth and dividend
Revenue growth13% · Above median
Dividend yield (TTM)0.9% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sun Pharmaceutical Industries Limited (SUNPHARMA) overvalued or undervalued?
As of Sep 17, 2026, our model estimates a fair value of ₹1,979 versus a price of ₹1,837, about +8% upside (fairly valued).
What is the fair value of SUNPHARMA?
Our model-based fair value for Sun Pharmaceutical Industries Limited is ₹1,979 (as of Sep 17, 2026), built from audited fundamentals. The current price: ₹1,837.
What is the quality score of SUNPHARMA?
Sun Pharmaceutical Industries Limited has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Our model-based price target is the fair value of ₹1,979 (as of Sep 17, 2026) from 26 valuation models. Cautious scenario ₹1,212, optimistic scenario ₹2,701. It is a calculation from audited fundamentals, not an analyst target.
What is the Sun Pharmaceutical Industries Limited stock forecast for 2026?
Our models put fair value at ₹1,979, about +8% upside versus a price of ₹1,837 (fairly valued). Cautious scenario ₹1,212, optimistic scenario ₹2,701. The calculation is refreshed regularly with new filings.
What is the revenue of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Sun Pharmaceutical Industries Limited reported trailing-twelve-month revenue of about ₹585B (latest available figure, as of Sep 17, 2026).
Does Sun Pharmaceutical Industries Limited pay a dividend?
Sun Pharmaceutical Industries Limited currently shows a dividend yield of about 0.90% relative to its recent price (as of Sep 17, 2026).
What growth is priced into Sun Pharmaceutical Industries Limited (SUNPHARMA)?
For today's price to be fair in a discounted-cash-flow model, Sun Pharmaceutical Industries Limited would have to grow free cash flow by +26.7 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.8 % per year. As of Sep 17, 2026.
What discount rate (WACC) does the fair value of SUNPHARMA use?
Our models discount Sun Pharmaceutical Industries Limited at 10.4 %: a base by market capitalisation (large), damped by beta 0.08, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sun Pharmaceutical Industries Limited that is +26.7 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Sun Pharmaceutical Industries Limited (SUNPHARMA) delivered so far?
Over the past 5 years revenue at Sun Pharmaceutical Industries Limited grew +11.8 % a year. The price currently implies +26.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sun Pharmaceutical Industries Limited (SUNPHARMA) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Sun Pharmaceutical Industries Limited (+26.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The free-cash-flow yield on the price is 2.09 %: that much free cash flow Sun Pharmaceutical Industries Limited produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sun Pharmaceutical Industries Limited it is ₹1,979 per share (as of Sep 17, 2026), against a price of ₹1,837. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sun Pharmaceutical Industries Limited stock overvalued or undervalued in 2026?
As of Sep 17, 2026, SUNPHARMA trades below its calculated fair value: price ₹1,837, fair value ₹1,979, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SUNPHARMA?
No. The price is what the market pays today (₹1,837); the fair value is what the company's own numbers justify (₹1,979). For Sun Pharmaceutical Industries Limited the two are ₹141.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sun Pharmaceutical Industries Limited worth?
The market values Sun Pharmaceutical Industries Limited at about ₹4.4T (market capitalisation, as of Sep 17, 2026). Per share that is ₹1,837; our models calculate a fair value of ₹1,979 per share.
What do the bullish and bearish scenarios say about SUNPHARMA?
Our models span a range for Sun Pharmaceutical Industries Limited: cautious scenario ₹1,212, base ₹1,979, optimistic ₹2,701 per share (as of Sep 17, 2026, price ₹1,837). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SUNPHARMA?
Sun Pharmaceutical Industries Limited trades at a price-to-earnings ratio of 38.5 (as of Sep 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,979 is built from several models across several years. Other multiples: PEG 1.0, P/B 5.6, P/S 7.9, EV/EBITDA 27.7.
What is the PEG ratio of SUNPHARMA?
The PEG ratio of Sun Pharmaceutical Industries Limited is 1.04 (P/E divided by earnings growth, as of Sep 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Balance-sheet figures for Sun Pharmaceutical Industries Limited (as of Sep 17, 2026): return on equity 14.7%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is SUNPHARMA from its 52-week high?
Sun Pharmaceutical Industries Limited trades at ₹1,837, about 4% below its 52-week high of ₹1,917 and 19% above the low of ₹1,538 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,979 is for.
Which stocks are comparable to Sun Pharmaceutical Industries Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sun Pharmaceutical Industries Limited stock attractive at the current price?
The data as of Sep 17, 2026: price ₹1,837, calculated fair value ₹1,979 (+8%), Quality Score 65/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SUNPHARMA calculated?
We run Sun Pharmaceutical Industries Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,979, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Sun Pharmaceutical Industries Limited currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The closing price on Sep 18, 2026 was ₹1,837. Our model-based fair value is ₹1,979, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sun Pharmaceutical Industries Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹1,212 to ₹2,701) leaves room in how you read the outcome.
Where does the earnings growth of Sun Pharmaceutical Industries Limited (SUNPHARMA) come from?
Earnings per share at Sun Pharmaceutical Industries Limited grew +7.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +7.0 %, EBIT margin −2.3 %, tax rate −0.5 %, residual (interest, one-offs) +3.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sun Pharmaceutical Industries Limited
How large is the market capitalisation of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The market capitalisation of Sun Pharmaceutical Industries Limited is ₹4.4T (≈ $45.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The price-to-sales ratio of Sun Pharmaceutical Industries Limited is 7.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Earnings per share at Sun Pharmaceutical Industries Limited are ₹47.74 (price ÷ EPS = P/E 38.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The dividend yield of Sun Pharmaceutical Industries Limited is 0.9% (payout 34.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The net margin of Sun Pharmaceutical Industries Limited is 19.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The return on equity (ROE) of Sun Pharmaceutical Industries Limited is 14.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
On an EBIT basis the return on assets of Sun Pharmaceutical Industries Limited is 24.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sun Pharmaceutical Industries Limited (SUNPHARMA)?
The operating margin of Sun Pharmaceutical Industries Limited is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Revenue at Sun Pharmaceutical Industries Limited is growing +12.8% versus a year earlier (3y avg +10.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sun Pharmaceutical Industries Limited (SUNPHARMA)?
Earnings per share at Sun Pharmaceutical Industries Limited are growing +25.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sun Pharmaceutical Industries Limited (SUNPHARMA) hold?
Sun Pharmaceutical Industries Limited holds more cash than debt, ₹70.1B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sun Pharmaceutical Industries Limited in the live analysis
One click puts Sun Pharmaceutical Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
